Dokument: [18F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference?
| Titel: | [18F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference? | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68618 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250213-122407-0 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Jannusch, Kai [Autor] Morawitz, Janna [Autor] Schweiger, Bernd [Autor] Weiss, Daniel [Autor] Schimmöller. Lars [Autor] Minko, Peter [Autor] Herrmann, Ken [Autor] Fendler, Wolfgang Peter [Autor] Quick, Harald H. [Autor] Antoch, Gerald [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | Contrast media, Positron-emission tomography, Lymphoma, Neoplasm staging, Magnetic resonance imaging | |||||||
| Beschreibung: | Objectives
Evaluate the influence of an MRI contrast agent application on primary and follow-up staging in pediatric patients with newly diagnosed lymphoma using [18F]FDG PET/MRI to avoid adverse effects and save time and costs during examination. Methods A total of 105 [18F]FDG PET/MRI datasets were included for data evaluation. Two different reading protocols were analyzed by two experienced readers in consensus, including for PET/MRI-1 reading protocol unenhanced T2w and/or T1w imaging, diffusion-weighted imaging (DWI), and [18F]FDG PET imaging and for PET/MRI-2 reading protocol an additional T1w post contrast imaging. Patient-based and region-based evaluation according to the revised International Pediatric Non-Hodgkin’s Lymphoma (NHL) Staging System (IPNHLSS) was performed, and a modified standard of reference was applied comprising histopathology and previous and follow-up cross-sectional imaging. Differences in staging accuracy were assessed using the Wilcoxon and McNemar tests. Results In patient-based analysis, PET/MRI-1 and PET/MRI-2 both determined a correct IPNHLSS tumor stage in 90/105 (86%) exams. Region-based analysis correctly identified 119/127 (94%) lymphoma-affected regions. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy for PET/MRI-1 and PET/MRI-2 were 94%, 97%, 90%, 99%, 97%, respectively. There were no significant differences between PET/MRI-1 and PET/MRI-2. Conclusions The use of MRI contrast agents in [18F]FDG PET/MRI examinations has no beneficial effect in primary and follow-up staging of pediatric lymphoma patients. Therefore, switching to a contrast agent–free [18F]FDG PET/MRI protocol should be considered in all pediatric lymphoma patients. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Jannusch, K., Morawitz, J., Schweiger, B., Weiß, D. A., Schimmöller, L., Minko, P., Herrmann, K., Fendler, W. P., Quick, H. H., Antoch, G., Umutlu, L., Kirchner, J. P., & Bruckmann, N.-M. (2023). [18F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference? European Radiology, 33(11), 8366–8375. https://doi.org/10.1007/s00330-023-09840-5 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 13.02.2025 | |||||||
| Dateien geändert am: | 13.02.2025 |
